- Home
- PSBD vs MAZE Comparison
PSBD vs MAZE Comparison
Compare PSBD & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSBD
- MAZE
- Stock Information
- Founded
- PSBD 2009
- MAZE 2018
- Country
- PSBD United States
- MAZE United States
- Employees
- PSBD N/A
- MAZE N/A
- Industry
- PSBD
- MAZE
- Sector
- PSBD
- MAZE
- Exchange
- PSBD Nasdaq
- MAZE NYSE
- Market Cap
- PSBD 454.8M
- MAZE 367.0M
- IPO Year
- PSBD 2024
- MAZE 2025
- Fundamental
- Price
- PSBD $14.12
- MAZE $15.73
- Analyst Decision
- PSBD Buy
- MAZE Strong Buy
- Analyst Count
- PSBD 4
- MAZE 4
- Target Price
- PSBD $14.13
- MAZE $23.50
- AVG Volume (30 Days)
- PSBD 36.5K
- MAZE 124.6K
- Earning Date
- PSBD 08-07-2025
- MAZE 08-14-2025
- Dividend Yield
- PSBD 12.57%
- MAZE N/A
- EPS Growth
- PSBD N/A
- MAZE N/A
- EPS
- PSBD N/A
- MAZE 0.34
- Revenue
- PSBD N/A
- MAZE $167,500,000.00
- Revenue This Year
- PSBD N/A
- MAZE N/A
- Revenue Next Year
- PSBD N/A
- MAZE N/A
- P/E Ratio
- PSBD N/A
- MAZE $47.25
- Revenue Growth
- PSBD N/A
- MAZE N/A
- 52 Week Low
- PSBD $11.51
- MAZE $6.71
- 52 Week High
- PSBD $16.85
- MAZE $17.00
- Technical
- Relative Strength Index (RSI)
- PSBD 54.82
- MAZE N/A
- Support Level
- PSBD $13.89
- MAZE N/A
- Resistance Level
- PSBD $14.62
- MAZE N/A
- Average True Range (ATR)
- PSBD 0.52
- MAZE 0.00
- MACD
- PSBD -0.02
- MAZE 0.00
- Stochastic Oscillator
- PSBD 50.39
- MAZE 0.00
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.